Avelumab for glioma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 19 Oct 2018: Trial started, NCT03893903
  2. 28 Mar 2019: Trial registered, NCT03893903

The trials

NCT03893903: AMPLIFYing NEOepitope-specific VACcine Responses in Progressive Diffuse Glioma

State
Completed
Phase
Phase 1
People
69 taking part
Started
19 Oct 2018
Primary completion
20 Sep 2024
Arms
Avelumab
Results
None posted
  1. 19 Oct 2018: Trial started
  2. 28 Mar 2019: Trial registered
  3. 20 Sep 2024: Trial completed

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

About the treatment

Kind of treatment: Drug.

Also known as Bavencio.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.